Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $24.8 million.

  • Intellia Therapeutics' Current Deferred Revenue fell 4462.71% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year decrease of 4462.71%. This contributed to the annual value of $38.9 million for FY2024, which is 3619.43% down from last year.
  • Intellia Therapeutics' Current Deferred Revenue amounted to $24.8 million in Q3 2025, which was down 4462.71% from $29.7 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Current Deferred Revenue peaked at $127.2 million during Q4 2021, and registered a low of $24.8 million during Q3 2025.
  • For the 5-year period, Intellia Therapeutics' Current Deferred Revenue averaged around $62.2 million, with its median value being $55.6 million (2024).
  • In the last 5 years, Intellia Therapeutics' Current Deferred Revenue skyrocketed by 16646.79% in 2021 and then tumbled by 6761.83% in 2023.
  • Intellia Therapeutics' Current Deferred Revenue (Quarter) stood at $127.2 million in 2021, then plummeted by 49.88% to $63.8 million in 2022, then fell by 4.36% to $61.0 million in 2023, then plummeted by 36.19% to $38.9 million in 2024, then crashed by 36.31% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q3 2025, $29.7 million for Q2 2025, and $33.8 million during Q1 2025.